A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)